CN103554030A - 苯达莫司汀游离碱的新颖形式 - Google Patents

苯达莫司汀游离碱的新颖形式 Download PDF

Info

Publication number
CN103554030A
CN103554030A CN201310425128.8A CN201310425128A CN103554030A CN 103554030 A CN103554030 A CN 103554030A CN 201310425128 A CN201310425128 A CN 201310425128A CN 103554030 A CN103554030 A CN 103554030A
Authority
CN
China
Prior art keywords
bendamustine free
free alkali
ray powder
powder diffraction
crystallized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201310425128.8A
Other languages
English (en)
Chinese (zh)
Inventor
劳伦特·D·库瓦西耶
马克·伊迪莱斯顿
柯蒂斯·R·哈尔蒂万格
罗伯特·E·麦凯恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42008533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103554030(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon LLC filed Critical Cephalon LLC
Publication of CN103554030A publication Critical patent/CN103554030A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
CN201310425128.8A 2009-01-15 2010-01-14 苯达莫司汀游离碱的新颖形式 Pending CN103554030A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14484309P 2009-01-15 2009-01-15
US61/144,843 2009-01-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201080004743.6A Division CN102281877B (zh) 2009-01-15 2010-01-14 苯达莫司汀的游离碱形式

Publications (1)

Publication Number Publication Date
CN103554030A true CN103554030A (zh) 2014-02-05

Family

ID=42008533

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310425128.8A Pending CN103554030A (zh) 2009-01-15 2010-01-14 苯达莫司汀游离碱的新颖形式
CN201080004743.6A Expired - Fee Related CN102281877B (zh) 2009-01-15 2010-01-14 苯达莫司汀的游离碱形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201080004743.6A Expired - Fee Related CN102281877B (zh) 2009-01-15 2010-01-14 苯达莫司汀的游离碱形式

Country Status (16)

Country Link
US (1) US8076366B2 (cg-RX-API-DMAC7.html)
EP (1) EP2387400A1 (cg-RX-API-DMAC7.html)
JP (1) JP2012515210A (cg-RX-API-DMAC7.html)
KR (1) KR20110110293A (cg-RX-API-DMAC7.html)
CN (2) CN103554030A (cg-RX-API-DMAC7.html)
AU (2) AU2010204765A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI1004922A2 (cg-RX-API-DMAC7.html)
CA (1) CA2749101A1 (cg-RX-API-DMAC7.html)
EA (1) EA020767B1 (cg-RX-API-DMAC7.html)
IL (1) IL213725A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011007557A (cg-RX-API-DMAC7.html)
NZ (1) NZ594010A (cg-RX-API-DMAC7.html)
SG (1) SG172810A1 (cg-RX-API-DMAC7.html)
UA (1) UA109109C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010083276A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201105099B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9376394B2 (en) * 2009-12-23 2016-06-28 Dr. Reddy's Laboratories Ltd. Preparation of bendamustine and its salts
WO2011094565A1 (en) 2010-01-28 2011-08-04 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
EP2720547A4 (en) * 2011-06-20 2014-11-05 Hetero Research Foundation PROCESS FOR BENDAMUSTINE HYDROCHLORIDE
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
ES2972227T3 (es) 2012-03-20 2024-06-11 Eagle Pharmaceuticals Inc Formulaciones de bendamustina
HRP20230276T1 (hr) 2012-03-20 2023-04-28 Eagle Pharmaceuticals, Inc. Tekući pripravci bendamustina za uporabu u postupku liječenja stanja koja reagiraju na bendamustin kod pacijenata kojima za primjenu trebaju reducirani volumeni
CA2904143A1 (en) 2013-03-12 2014-10-09 Cephalon, Inc. Nanoparticulate and macroparticulate formulations
WO2014176070A1 (en) 2013-04-26 2014-10-30 Vital Art & Science Incorporated Contour integration perimetry vision test
US20240148696A1 (en) 2022-10-25 2024-05-09 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE80967C (cg-RX-API-DMAC7.html)
DE159877C (cg-RX-API-DMAC7.html)
DE293808C (cg-RX-API-DMAC7.html)
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DD159877A1 (de) * 1981-06-12 1983-04-13 Wolfgang Krueger Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure
US5204335A (en) 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US5227373A (en) 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5741523A (en) 1993-10-27 1998-04-21 Pharmacia & Upjohn Company Stabilized prostaglandin E1
US5561121A (en) 1993-11-09 1996-10-01 American Cyanamid Company Stable lyophilized thiotepa composition
US5955504A (en) 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (de) 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6077850A (en) 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US20040072889A1 (en) 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
JP2002520282A (ja) 1998-07-09 2002-07-09 フランシス エイ. ナーデラ, 慢性リンパ性白血病の処置のための方法および組成物
US5972912A (en) 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
DE10016077A1 (de) 2000-03-31 2001-12-13 Cellcontrol Biomedical Lab Gmb Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen
US20040152672A1 (en) 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
KR20040025881A (ko) 2000-12-11 2004-03-26 다케다 야쿠힌 고교 가부시키가이샤 개선된 흡수성을 갖는 의약 조성물
PL362979A1 (en) 2000-12-11 2004-11-02 Takeda Chemical Industries, Ltd. Medicinal compositions improved in solublity in water
DK1435877T3 (da) 2001-10-15 2009-08-03 Hemoteq Ag Overtrækning af stents for at forhindre restenose
US6613927B1 (en) 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
DE10306724A1 (de) 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
AU2003221517B2 (en) 2002-03-22 2010-02-18 Christian Straka Cytocapacity test
EP1354952A1 (en) 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
WO2003086470A2 (en) 2002-04-17 2003-10-23 Deutsches Krebsforschungszentrum Smac-peptides as therapeutics against cancer and autoimmune diseases
EP1501565B1 (de) 2002-05-09 2006-11-02 Hemoteq GmbH Verbindungen und verfahren zur hemokompatiblen beschichtung von oberflächen
US20040096436A1 (en) 2002-08-02 2004-05-20 Regents Of The University Of California Methods for inhibiting protein kinases in cancer cells
DE10304403A1 (de) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
EP1594900A2 (en) 2003-02-14 2005-11-16 Salmedix, Inc. Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers
KR20060052880A (ko) 2003-07-25 2006-05-19 와이어쓰 동결건조된 cci- 779 제형
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
MX2011003751A (es) * 2008-10-08 2011-04-27 Cephalon Inc Procesos para preparar bendamustina.

Also Published As

Publication number Publication date
AU2016204902A1 (en) 2016-08-04
CN102281877B (zh) 2014-07-23
KR20110110293A (ko) 2011-10-06
UA109109C2 (uk) 2015-07-27
EA020767B1 (ru) 2015-01-30
EA201170934A1 (ru) 2011-12-30
CA2749101A1 (en) 2010-07-22
ZA201105099B (en) 2012-03-28
MX2011007557A (es) 2011-08-12
EP2387400A1 (en) 2011-11-23
US8076366B2 (en) 2011-12-13
BRPI1004922A2 (pt) 2019-09-24
NZ594010A (en) 2013-08-30
JP2012515210A (ja) 2012-07-05
SG172810A1 (en) 2011-08-29
CN102281877A (zh) 2011-12-14
US20100210701A1 (en) 2010-08-19
AU2010204765A1 (en) 2011-07-28
IL213725A0 (en) 2011-07-31
WO2010083276A1 (en) 2010-07-22

Similar Documents

Publication Publication Date Title
US20120309968A1 (en) Polymorphs of dasatinib, preparation methods and pharmaceutical compositions thereof
JP5394238B2 (ja) 短時間作用型ベンゾジアゼピンの塩およびその多型形態
US8076366B2 (en) Forms of bendamustine free base
CN103764637A (zh) 卡巴他赛的固态形式及其制备方法
CA2941087A1 (en) Ibrutinib solid forms and production process therefor
US20210332014A1 (en) Cabozantinib malate crystal form, preparation method and use thereof
US12209073B2 (en) Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitor
WO2013170142A1 (en) Solid state forms of fidaxomycin and processes for preparation thereof
RS59782B1 (sr) Hidroksietil sulfonat od ciklina zavisnog inhibitora kinaze proteina, njegov kristalni oblik, i postupak za njegovo dobijanje
EA025561B1 (ru) Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf
WO2014145600A1 (en) Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
WO2021000687A1 (zh) Pac-1晶型的制备方法
CN115974863B (zh) 占诺美林衍生物的苹果酸盐、a晶型及其制备方法和用途
US20170189367A1 (en) Lobaplatin Crystal, Preparation Method And Pharmaceutical Application
CN114105969A (zh) Btrx-335140的晶型及其制备方法
EP3178821B1 (en) 6-aryl amino pyridone formamide compound crystal and preparation method therefor
JP7152122B2 (ja) エダラボン塩
CN105777651A (zh) 聚腺苷酸二磷酸核糖转移酶抑制剂的晶型及其制备方法和医药用途
EP3473623B1 (en) Crystal forms of nbi-98854, preparation method therefor and use thereof
US9458148B2 (en) Crystalline form of masitinib
EP3816167B1 (en) Crystal of a benzoxazole derivative
CN108659038B (zh) 1-硬脂酰-2-丙戊酰-sn-甘油-3-磷脂酰胆碱的多晶型物及制备方法
US20250145588A1 (en) Crystal form of tavapadon, and preparation method therefor and use thereof
WO2012003413A1 (en) Novel solid forms of tacedinaline
CN108727417A (zh) 多环化合物钠盐及其多晶型、制备方法及应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140205